Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myasthaenia Gravis: later-stage trial registry
3 of 3 indexed Myasthaenia Gravis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Myasthaenia Gravis: 3 US clinical trials tracked, 3 recruiting.
Myasthaenia Gravis is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Kyverna Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition myasthaenia-gravis
OPEN 3 | RECR 100% | LATE 1 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Myasthaenia Gravis lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myasthaenia Gravis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myasthaenia Gravis is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Myasthenia Gravis Foundation of America Global MG Patient Registry
Myasthenia Gravis Foundation of America
NCT06617741
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Cartesian Therapeutics
NCT06799247
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Kyverna Therapeutics
NCT07403188
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Myasthaenia Gravis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myasthaenia Gravis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myasthaenia Gravis page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Myasthaenia Gravis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Kyverna Therapeutics sponsors the most Myasthaenia Gravis trials on record, review their full trial history before evaluating a specific study. See Kyverna Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myasthaenia Gravis condition card totals 3 registered trials; most-linked intervention KYV-101; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.